Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.

× No keyword cloud information.

12 in total

1. Self-plagiarism.

Authors: Bruce A Chabner
Journal: Oncologist Date: 2011

Review 2. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.

Authors: Dae Y Kim; Jose A Karam; Christopher G Wood
Journal: World J Urol Date: 2014-04-18 Impact factor: 4.226

Review 3. Early renal cell cancer.

Authors: Yoshihiko Tomita
Journal: Int J Clin Oncol Date: 2006-02 Impact factor: 3.402

4. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Authors: X Niu; T Zhang; L Liao; L Zhou; D J Lindner; M Zhou; B Rini; Q Yan; H Yang
Journal: Oncogene Date: 2011-07-04 Impact factor: 9.867

5. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors: C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal: Can Urol Assoc J Date: 2007-06 Impact factor: 1.862

6. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors: James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal: J Immunother Date: 2007 Nov-Dec Impact factor: 4.456

7. A brief symptom index for advanced renal cell carcinoma.

Authors: David T Eton; David Cella; Jennifer Bacik; Robert J Motzer
Journal: Health Qual Life Outcomes Date: 2006-09-26 Impact factor: 3.186

8. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.

Authors: M E Cianfrocca; K A Kimmel; J Gallo; T Cardoso; M M Brown; G Hudes; N Lewis; L Weiner; G N Lam; S C Brown; D E Shaw; A P Mazar; R B Cohen
Journal: Br J Cancer Date: 2006-06-05 Impact factor: 7.640

9. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.

Authors: D M Shaw; N B Connolly; P M Patel; S Kilany; G Hedlund; O Nordle; G Forsberg; J Zweit; P L Stern; R E Hawkins
Journal: Br J Cancer Date: 2007-02-06 Impact factor: 7.640

10. The contributions of HIF-target genes to tumor growth in RCC.

Authors: Ting Zhang; Xiaohua Niu; Lili Liao; Eun-Ah Cho; Haifeng Yang
Journal: PLoS One Date: 2013-11-18 Impact factor: 3.240